fda import alert semaglutide green list glp-1 tirzepatide 2025 SFDA updates guidelines for pharmaceutical variation requirements FDA Import Alert 66-80: GLP-1 – FDA launches green list for

it is only accessible through authorised clinical trials and is not available for routine prescribing

These actions improve glucose control and reduce hepatic glucose production

Tissue Repair and Injury Healing While BPC-157 is well-known for its ability to maintain healthy GI lining, the peptide is also known to stimulate healing in other tissues, including tendons, ligaments, muscles, and bones

Inflammatory versus neoplastic, mucinous versus non-mucinous, and duct communication remain the core branch points before surveillance or EUS-FNA is planned

I filled the prescription with barely a second thought

Its targeted mechanism of action, low hypoglycaemia risk, and excellent tolerability make it a valuable choice for long-term glycaemic control